gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin nv hold preclin data shine
highlight week octob novemb novarti unrat announc fda place partial hold
gene therapi gt market zolgensma intrathec clinic trial spinal muscular
atrophi sma patient base find small pre-clin anim studi show dorsal root ganglia mononuclear cell
inflamm neuron cell bodi degener partial hold affect strong phase i/ii trial
sma novarti previous report result cohort patient trial partial hold current
affect patient high-dos vg strong cohort compani report advers event
relat pre-clin find seen thorough review human safeti data avail
sourc date zolgensma iv dose expect remain market on-going clinic trial
test iv administr expect remain unaffect buy chardan top pick
announc posit final updat phase i/ii clinic trial gt b-vec rdeb
treat wound close complet averag durat wound closur last measur timepoint day krystal
plan start pivot trial possibl bla file buy announc
collabor research agreement roch unrat treatment chronic infect hepat viru
deal focus rnai-bas therapeut dcr-hbv test phase clinic trial
term agreement roch receiv world-wide licens therapi dicerna receiv
mm up-front addit bn achiev development commerci mileston dicerna
also retain option fund pivot develop dcr-hbv elig receiv royalti option
exercis two compani also agre collabor research develop addit therapi aim
chronic hepat infect present initi phase data expect crispr
buy announc vertex pharmaceut unrat exercis option in-licens product develop
use crispr-bas edit technolog target cystic fibrosi transmembran conduct regul
cftr undisclos term agreement crispr reciev mm up-front
mm develop commerci mileston target option grant vertex
agreement establish compani believ key valu add crispr
therapeut vertex remain right licens addit target collabor agreement
chardan annual genet medicin confer on-line survey avail
chardan annual genet medicin confer held new york citi octob
repres privat public compani investor around globe key opinion leader
total attende took part becom largest sell-sid confer focus field
genet medicin part continu coverag space post-confer survey avail
look forward novemb novemb novemb asgct polici summit held
buy orchard unrat swanbio privat novemb societi
immunotherapi cancer annual meet held nation harbor md agenda includ
poseida privat refug biotech privat replimun buy novemb uniqur buy
chardan top pick present huntington studi group hsg annual meet sacramento ca
novemb unrat present acr/arp annual meet atlanta ga
compani report result unrat novemb et
chardan top pick novemb et unrat novemb et
pleas refer import disclosur inform regul analyst certif found page report
unrat novemb et ocugen unrat novemb et selecta bioscienc unrat
novemb et novemb replimun host investor event edt annual
meet novemb host investor event edt annual meet
weekli price move vivo genet medicin aav srna mrna vivo gene edit
mrna mm vivo gene edit mm contributor buy mm
upcom chardan genet medicin event contact chardan rsvp
gene express on-demand gene therapi epilepsi
research team led dr christoph schwarzer medic univers innsbruck austria publish gene
therapi focal epilepsi util cellular machineri deliv on-demand therapi tempor lobe epilepsi
brief epilepsi neurolog disord world-wide preval disrupt normal cognit function
lead neuron loss patient suffer focal seizur unfortun mani form diseas
refractori current drug treatment may ultim requir neurosurgeri one promis target sustain
therapeut benefit dynorphin famili protein natur anticonvuls releas neuron vesicl
quell burst activ dr schwarzer colleagu develop gene deliveri vector base
backbon capsid express preprodynorphin cdna test construct mous model mesial
tempor lobe epilepsi record time point day treat mice experienc gener seizur
fewer hippocamp paroxysm discharg given time point hpd form sustain spike
neuron activ contrast control mice experienc hpd per hour period durat studi
known preprodynorphin store vesicl process releas respons excess neuron
activ studi shown vector-deliv dynorphin releas intracellular vesicl respons
stimul so-cal on-demand activ us repres step toward complex gene therapi
note approach reli cellular machineri regul consid promis synthet biolog
see march research particularli promot engin achiev control transgen express dr
schwarzer studi use promot cba promot expect drive high level gene express transgen
use promot tailor neuron tissu us would even promis therapeut approach synprom
recent acquir askbio privat engin gene therapi construct next-gener promot
optim express tissu select importantli synprom take approach use exist cellular
machineri transcript factor rather use exogen factor regul express
crsp buy focu execut boost collab cash octob livshit
crispr announc result provid updat clinic program dose initi
phase i/ii trial allogen car-t cancer follow-on asset
target bcma set enter clinic multipl myeloma compani remain track report
preliminari safeti efficaci data phase i/ii program sever transfusion-depend beta thalassemia
tdt sickl cell diseas scd
addit crispr announc collabor unrat exercis
option in-licens addit target develop crispr-bas therapeut crispr receiv
mm up-front mm mileston per target
page
option exercis follow expans collabor compani conjunct vertex
acquisit exon announc june crispr cash posit
mm us place compani strong posit focu execut
buy mfg begin attr piec come togeth tcr tx octob livshit
intellia report result re-affirmed guidanc program preclin present
modal last week european societi gene cell therapi annual congress barcelona
compani remain track submit ind lead vivo asset deliv crispr
compon lipid nanoparticl lnp treat transthyretin amyloidosi attr compani begun clinical-
scale manufactur plan phase trial
ex vivo side intellia track nomin develop candid autolog cell receptor
tcr -engin cell-bas therapi treat cancer compani esgct present
encouragingli demonstr intellia crispr-bas target tcr insert strategi effici
buy pt multipl potenti catalyst novemb naka
report result re-affirmed guidanc program announc includ
sale figur rnai therapeut onpattro mm repres sequenti increas rel
compani highlight select numer upcom mileston regulatori file potenti catalyst
alnylam us clear leader rnai space valid platform readi access capit strateg
invest commerci oper market natur interest onpattro earli sale
result believ investor focu promis big pictur compani
buy pt rais pt influx collabor deal novemb naka
announc new research collabor licens agreement roch unrat
develop novel therapi treatment chronic hepat viru infect agreement focus world-wide
develop commerci rnai-bas therapeut dcr-hbv current phase clinic trial
also specifi develop addit therapi target hepat viru
view agreement posit develop occur sooner higher up-front amount
million expect reiter buy rate increas pt attract licens deal
genet medicin news octob novemb
unrat collabor md anderson tcr-t clinic trial cancer octob
qure buy report result provid busi updat octob
buy announc appoint dr judith abram chief medic offic octob
uiowa publish deliveri crispr-associ nucleas epitheli cell airway octob
carsgen privat receiv rmat design car-t therapi r/r multipl myeloma octob
rhhbi unrat announc extens tender offer neutral octob
ise neutral announc appoint dr abraham scaria chief scientif offic octob
unrat report result provid corpor updat octob
cll unrat announc patient dose pi trial off-the-shelf car-t tx r/r mm octob
mdco buy report result provid updat busi oper octob
nv unrat announc updat pi/ii trial gt sma type octob
novarti announc fda decis place partial hold affect phase i/ii clinic trial
test intrathec dose gene therapi sma type basi pre-clin find
show inflamm cell loss dorsal root ganglion partial hold affect enrol high-dos
hold affect market zolgensma studi dose intraven administr
manag complet review safeti data state advers effect relat sensori chang
seen intrathec zolgensma
unrat initi enrol piii lead-in trial aav-bas gt hema octob
ieo publish rna aptam deliveri mirna therapeut b-cell octob
gener privat announc appoint dr steven dowdi advisori board octob
page
buy announc updat pi/ii trial hsv-base gt rdeb octob
passag privat announc appoint richard morri chief offic octob
neutral announc appoint peter soparkar chief legal offic octob
unrat report result provid commerci pipelin updat octob
unrat report result provid updat oper progress octob
arranta privat announc partnership thermo fisher unrat gt manufactur octob
unrat announc ind clearanc adenovirus-bas gt osteoarthr octob
qure buy publish interim result piib studi gt hemophilia octob
bntc unrat report financi result provid updat busi oper octob
tx privat announc collabor prime medicin privat prime edit tech octob
buy report result provid updat oper octob
alsen fp unrat report result provid updat gt collabor octob
sumitomo dainippon pharma unrat announc roivant privat strateg allianc octob
sumitomo dainippon pharma part term allianc acquir roivant ownership subsidiari
option exercis acquir interest addit subsidiari compani plan consolid
subsidiari privat altav scienc privat enzyv therapeut unrat myovant scienc privat
spirov scienc unrat urov scienc new compani led ceo myrtl potter
least gene therapi asset transfer part deal includ spirov raav-bas
lentivirus-bas cystic fibrosi urov plasmid dna-
base overact bladder
unrat present interim phase i/ii trial data mrna therapeut cystic fibrosi octob
unrat announc kamran alam svp financ princip offic octob
nci publish self-inactiv lentiviru deliv therapeut hiv octob
buy present preclin data rnai-bas therapeut aro-enac cystic fibrosi octob
arrowhead pharmaceut present north american cystic fibrosi confer data rnai-bas
therapeut aro-enac compani develop aro-enac first inhal pulmonari program drug
use epitheli target ligand rnai trigger target enac mrna sheep model compani
show singl inhal dose aro-enac suffici induc mucociliari clearanc specif
dose approxim doubl clearanc day led partial elev clearanc day clearanc
twice baselin day sheep receiv higher dose
arrowhead expand effort develop rnai target outsid liver highlight recent day
see octob research larg anim data support compani plan file bla aro-enac
cystic fibrosi
sichuan univers publish gt mous model wilson diseas octob
aist publish sendai virus-bas vector therapeut microrna express platform octob
unrat report financi result provid updat busi oper octob
unrat announc appoint sung evp chief offic novemb
compani mention report
page
page
select catalyst genet medicin coverag
figur regenxbio replimun solid uniqur expect import data read-out
aro-aat initi phase ii/iii studi liver diseas
lumasiran initi illuminate-c phase trial
initi phase i/ii clinic trial huntington diseas
initi phase i/ii trial dmd nationwid children hospit
report interim efficaci readout phase oval trial ovarian cancer
report dose escal data pi/ii trial achm
dcr-hbv anticip first interim data clinic trial hbv
provid initi data phase trial gangliosidosi
axo-lenti-pd report data cohort sunrise-pd phase ii trial
submit ind methylmalon acidemia mma
present data phase portion solid tumor trial /- nivolumab
file ind phase ii studi diabet retinopathi dr
present interim data pi/ii studi mp ii pi studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
initi dose phase trial hemophilia
initi patient dose brillianc phase i/ii trial
report result phase i/ii ignit dmd trial
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
file ind huntington diseas program
present preclin data new gt program fabri pomp defici
provid follow-up data piib dose-confirm studi hemb
file ind cta pomp diseas
dose patient phase studi mp
provid updat phase i/ii studi hemophilia
declar develop candid aml
initi phase trial dystroph epidermolysi bullosa deb
report preliminari data phase i/ii trial hemoglobinopathi
page
select catalyst outsid genet medicin coverag
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
valrox submit bla pend fda feedback hemophilia
initi pivot phase trial rdeb
initi phase data patient leukocyt adhes deficiency-i lad-i
report initi phase data process fanconi anemia
suvodirsen interim data open-label extens studi dmd
initi patient dose phase studi pyruv kinas defici pkd
initi us phase ii studi fanconi anemia
initi phase i/ii trial parkinson diseas mutat
initi phase ib trial beta-thalassemia
initi phase trial multipl myeloma
initi clinic trial charcot-marie-tooth type
file approv transit clinic trial platform manufactur
micro-dystrophin initi pivot trial duchenn muscular dystrophi
initi phase ii studi overact bladder
initi phase i/ii studi best diseas
micro-dystrophin initi confirmatori trial commerci materi dmd
begin patient dose phase trial
file ind inherit amyotroph later sclerosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
sea-bcma report preliminari phase dose escal data r/r mm
lentiglobin initi phase studi sickl cell diseas
zynteglo initi roll bla submiss fda tdt
report initi data phase i/ii trial phenylketonuria pku
rituximab report preliminari phase cohort data r/r nhl
file ind gangliosidosi
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma buy lysogen oncosec medic oxford biomedica neutral vbl neutral
figur select price movement week end vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm iver genet therapytickerratingccm ptupsideclosechang changemc mm arbutu gene editingtickerratingccm ptupsideclosechang changemc mm crispr pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note though avx nite acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap pharmaceut
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid technolog
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name bntx model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani pharmaceut
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan recombinet trucod gene repair verv technolog pharmaceut
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
swedish orphan biovitrum astrazeneca
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
price prv
page
date fda rpdd
ultragenyx genetx
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genetx ultragenyx
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
